Azupedia

Biosimilar/ja: Difference between revisions

Biosimilar/ja
← Older editNewer edit →
VisualWikitext
Created page with "== さらに読む == * {{cite journal | vauthors = Udpa N, Million RP | title = Monoclonal antibody biosimilars | journal = Nature Reviews. Drug Discovery | volume = 15 | issue = 1 | pages = 13–4 | date = January 2016 | pmid = 26678619 | doi = 10.1038/nrd.2015.12 | s2cid = 27954836 }} * {{cite journal | vauthors = Jelkmann W | title = Biosimilar epoetins and other "follow-on" biologics: update on the European experiences | journal = American Journal of Hematology | vo..."
Tags: Mobile edit Mobile web edit
Created page with "{| class="wikitable" |- ! バイオシミラーFDA承認日 !! バイオシミラー製品 !! オリジナル製品 |- | March 2015 || filgrastim-sndz/Zarxio || filgrastim/ja/Neupogen |- | April 2016 || infliximab-dyyb/Inflectra || infliximab/ja/Remicade |- | August 2016 || etanercept-szzs/Erelzi || etanercept/ja/Enbrel |- | September 2016 || adalimumab-atto/Amjevita || adalimumab/ja/Humira |- | April 2017 || infliximab-abda/Renflexis || infliximab/ja..."
Tags: Mobile edit Mobile web edit
Line 178: Line 178:
===アメリカで承認されたバイオシミラー===
===アメリカで承認されたバイオシミラー===


<div lang="en" dir="ltr" class="mw-content-ltr">
{| class="wikitable"
{| class="wikitable"
|-
|-
! Date of Biosimilar FDA Approval !! Biosimilar Product !! Original Product
! バイオシミラーFDA承認日 !! バイオシミラー製品 !! オリジナル製品
|-
|-
| March 2015 || filgrastim-sndz/Zarxio || [[filgrastim]]/Neupogen
| March 2015 || filgrastim-sndz/Zarxio || [[filgrastim/ja]]/Neupogen
|-
|-
| April 2016 || infliximab-dyyb/Inflectra || [[infliximab]]/Remicade
| April 2016 || infliximab-dyyb/Inflectra || [[infliximab/ja]]/Remicade
|-
|-
| August 2016 || etanercept-szzs/Erelzi || [[etanercept]]/Enbrel
| August 2016 || etanercept-szzs/Erelzi || [[etanercept/ja]]/Enbrel
|-
|-
| September 2016 || adalimumab-atto/Amjevita || [[adalimumab]]/Humira
| September 2016 || adalimumab-atto/Amjevita || [[adalimumab/ja]]/Humira
|-
|-
| April 2017 || infliximab-abda/Renflexis || [[infliximab]]/Remicade
| April 2017 || infliximab-abda/Renflexis || [[infliximab/ja]]/Remicade
|-
|-
| August 2017 || adalimumab-adbm/Cyltezo || [[adalimumab]]/Humira
| August 2017 || adalimumab-adbm/Cyltezo || [[adalimumab/ja]]/Humira
|-
|-
| September 2017 || bevacizumab-awwb/Mvasi || [[bevacizumab]]/Avastin
| September 2017 || bevacizumab-awwb/Mvasi || [[bevacizumab/ja]]/Avastin
|-
|-
| December 2017 || trastuzumab-dkst/Ogivri || [[trastuzumab]]/Herceptin
| December 2017 || trastuzumab-dkst/Ogivri || [[trastuzumab/ja]]/Herceptin
|-
|-
| December 2017 || infliximab-qbtx/Ixifi || [[infliximab]]/Remicade
| December 2017 || infliximab-qbtx/Ixifi || [[infliximab/ja]]/Remicade
|-
|-
| May 2018 || epoetin alfa-epbx/Retacrit || [[epoetin alfa]]/Procrit
| May 2018 || epoetin alfa-epbx/Retacrit || [[epoetin alfa/ja]]/Procrit
|-
|-
|June 2018 || pegfilgrastim-jmdb/Fulphila || [[pegfilgrastim]]/Neulasta
|June 2018 || pegfilgrastim-jmdb/Fulphila || [[pegfilgrastim/ja]]/Neulasta
|-
|-
| July 2018 || filgrastim-aafi/Nivestym || [[filgrastim]]/Neupogen
| July 2018 || filgrastim-aafi/Nivestym || [[filgrastim/ja]]/Neupogen
|-
|-
| October 2018 || adalimumab-adaz/Hyrimoz || [[adalimumab]]/Humira
| October 2018 || adalimumab-adaz/Hyrimoz || [[adalimumab/ja]]/Humira
|-
|-
| November 2018 || pegfilgrastim-cbqv/Udenyca || [[pegfilgrastim]]/Neulasta
| November 2018 || pegfilgrastim-cbqv/Udenyca || [[pegfilgrastim/ja]]/Neulasta
|-
|-
| November 2018 || rituximab-abbs/Truxima || [[rituximab]]/Rituxan
| November 2018 || rituximab-abbs/Truxima || [[rituximab/ja]]/Rituxan
|-
|-
| December 2018 || trastuzumab-pkrb/Herzuma || [[trastuzumab]]/Herceptin
| December 2018 || trastuzumab-pkrb/Herzuma || [[trastuzumab/ja]]/Herceptin
|-
|-
| January 2019 || trastuzumab-dttb/Ontruzant || [[trastuzumab]]/Herceptin
| January 2019 || trastuzumab-dttb/Ontruzant || [[trastuzumab/ja]]/Herceptin
|-
|-
| March 2019 || trastuzumab-qyyp/Trazimera || [[trastuzumab]]/Herceptin
| March 2019 || trastuzumab-qyyp/Trazimera || [[trastuzumab/ja]]/Herceptin
|-
|-
| April 2019 || etanercept-ykro/Eticovo || [[etanercept]]/Enbrel
| April 2019 || etanercept-ykro/Eticovo || [[etanercept/ja]]/Enbrel
|-
|-
| June 2019 || trastuzumab-anns/Kanjinti || [[trastuzumab]]/Herceptin
| June 2019 || trastuzumab-anns/Kanjinti || [[trastuzumab/ja]]/Herceptin
|-
|-
| June 2019 || bevacizumab-bvzr/Zirabev || [[bevacizumab]]/Avastin
| June 2019 || bevacizumab-bvzr/Zirabev || [[bevacizumab/ja]]/Avastin
|-
|-
| July 2019 || rituximab-pvvr/Ruxience || [[rituximab]]/Rituxan
| July 2019 || rituximab-pvvr/Ruxience || [[rituximab/ja]]/Rituxan
|-
|-
| July 2019 || adalimumab-bwwd/Hadlima || [[adalimumab]]/Humira
| July 2019 || adalimumab-bwwd/Hadlima || [[adalimumab/ja]]/Humira
|-
|-
| November 2019 || pegfilgrastim-bmez/Ziextenzo || [[pegfilgrastim]]/Neulasta
| November 2019 || pegfilgrastim-bmez/Ziextenzo || [[pegfilgrastim/ja]]/Neulasta
|-
|-
| November 2019 || adalimumab-afzb/Abrilada || [[adalimumab]]/Humira
| November 2019 || adalimumab-afzb/Abrilada || [[adalimumab/ja]]/Humira
|-
|-
| December 2019 || infliximab-axxq/Avsola || [[infliximab]]/Remicade
| December 2019 || infliximab-axxq/Avsola || [[infliximab/ja]]/Remicade
|-
|-
| June 2020 || pegfilgrastim-apgf/Nyvepria || [[pegfilgrastim]]/Neulasta
| June 2020 || pegfilgrastim-apgf/Nyvepria || [[pegfilgrastim/ja]]/Neulasta
|-
|-
| July 2020 || adalimumab-fkjp/Hulio || [[adalimumab]]/Humira
| July 2020 || adalimumab-fkjp/Hulio || [[adalimumab/ja]]/Humira
|-
|-
| December 2020 || rituximab-arrx/Riabni || [[rituximab]]/Rituxan
| December 2020 || rituximab-arrx/Riabni || [[rituximab/ja]]/Rituxan
|-
|-
| July 2021|| insulin glargine-yfgn/Semglee || [[insulin glargine]]/Lantus
| July 2021|| insulin glargine-yfgn/Semglee || [[insulin glargine/ja]]/Lantus
|-
|-
| September 2021 || ranibizumab-nuna/Byooviz || [[ranibizumab]]/Lucentis
| September 2021 || ranibizumab-nuna/Byooviz || [[ranibizumab]]/Lucentis
|-
|-
| December 2021 || insulin glargine-aglr/Rezvoglar || [[insulin glargine]]/Lantus
| December 2021 || insulin glargine-aglr/Rezvoglar || [[insulin glargine/ja]]/Lantus
|-
|-
| December 2021 || adalimumab-aqvh/Yusimry || [[adalimumab]]/Humira
| December 2021 || adalimumab-aqvh/Yusimry || [[adalimumab/ja]]/Humira
|-
|-
| February 2022 || filgrastim-ayow/Releuko || [[filgrastim]]/Neupogen
| February 2022 || filgrastim-ayow/Releuko || [[filgrastim/ja]]/Neupogen
|-
|-
| April 2022 || bevacizumab-maly/Alymsys || [[bevacizumab]]/Avastin
| April 2022 || bevacizumab-maly/Alymsys || [[bevacizumab/ja]]/Avastin
|-
|-
| May 2022 || pegfilgrastim-pbbk/Fylnetra || [[pegfilgrastim]]/Neulasta
| May 2022 || pegfilgrastim-pbbk/Fylnetra || [[pegfilgrastim/ja]]/Neulasta
|-
|-
| August 2022 || ranibizumab-eqrn/Cimerli || [[ranibizumab]]/Lucentis
| August 2022 || ranibizumab-eqrn/Cimerli || [[ranibizumab/ja]]/Lucentis
|-
|-
| September 2022|| pegfilgrastim-fpgk/Stimufend || [[pegfilgrastim]]/Neulasta
| September 2022|| pegfilgrastim-fpgk/Stimufend || [[pegfilgrastim/ja]]/Neulasta
|-
|-
| September 2022 || bevacizumab-adcd/Vegzelma || [[bevacizumab]]/Avastin
| September 2022 || bevacizumab-adcd/Vegzelma || [[bevacizumab/ja]]/Avastin
|-
|-
| December 2022 || adalimumab-aacf/Idacio || [[adalimumab]]/Humira
| December 2022 || adalimumab-aacf/Idacio || [[adalimumab/ja]]/Humira
|-
|-
| May 2023 || adalimumab-aaty/Yuflyma || [[adalimumab]]/Humira
| May 2023 || adalimumab-aaty/Yuflyma || [[adalimumab/ja]]/Humira
|-
|-
| August 2023 || natalizumab-sztn/Tyruko || [[natalizumab]]/Tysabri
| August 2023 || natalizumab-sztn/Tyruko || [[natalizumab/ja]]/Tysabri
|-
|-
| September 2023 || tocilizumab-bavi/Tofidence || [[tocilizumab]]/Actemra
| September 2023 || tocilizumab-bavi/Tofidence || [[tocilizumab/ja]]/Actemra
|-
|-
| October 2023 || ustekinumab-auub/Wezlana || [[ustekinumab]]/Stelara
| October 2023 || ustekinumab-auub/Wezlana || [[ustekinumab/ja]]/Stelara
|-
|-
| December 2023 || bevacizumab-tnjn/Avzivi || [[bevacizumab]]/Avastin
| December 2023 || bevacizumab-tnjn/Avzivi || [[bevacizumab/ja]]/Avastin
|-
|-
| February 2024 || adalimumab-ryvk/Simlandi || [[adalimumab]]/Humira
| February 2024 || adalimumab-ryvk/Simlandi || [[adalimumab/ja]]/Humira
|-
|-
| March 2024 || denosumab-bbdz/Jubbonti || [[denosumab]]/Prolia
| March 2024 || denosumab-bbdz/Jubbonti || [[denosumab/ja]]/Prolia
|-
|-
| March 2024 || denosumab-bbdz/Wyost || [[denosumab]]/Xgeva
| March 2024 || denosumab-bbdz/Wyost || [[denosumab/ja]]/Xgeva
|}
|}
</div>




Retrieved from "https://wiki.tiffa.net/wiki/Biosimilar/ja"